We are live on ! Find out more
TCM

Tybourne Capital Management Portfolio holdings

AUM $30.9M
1-Year Est. Return 20.1%
This Fund
S&P 500
This Quarter Est. Return
-3.14%
1 Year Est. Return
+20.1%
3 Year Est. Return
+108.99%
5 Year Est. Return
+80.28%
10 Year Est. Return
+751.59%
AUM
$1.04B
AUM Growth
-$344M
Cap. Flow
-$315M
Cap. Flow %
-30.25%
Top 10 Hldgs %
63.51%
Holding
27
New
Increased
2
Reduced
23
Closed
1

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$31.6M
2
LRCX icon
Lam Research
LRCX
+$10.5M

Top Sells

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$31.8M
2
TXN icon
Texas Instruments
TXN
+$29.6M
3
TEAM icon
Atlassian
TEAM
+$28.2M
4
CP icon
Canadian Pacific Kansas City
CP
+$27.9M
5
MSFT icon
Microsoft
MSFT
+$27M

Sector Composition

Rank Sector Weight
1 Technology 36.3%
2 Consumer Discretionary 22.8%
3 Financials 13.18%
4 Healthcare 8.96%
5 Industrials 7.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TSHA icon
26
Taysha Gene Therapies
TSHA
$1.82B
$965K 0.09%
500,000
AMLX icon
27
Amylyx Pharmaceuticals
AMLX
$2.69B
-768,603
Closed -$14.8M

Similar funds

Tybourne Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Tybourne Capital Management held 27 positions worth $1.04B, down 25% from $1.38B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Tybourne Capital Management withdrew a net $315M in Q3 2022, closing 1 position and reducing 23 holdings. Its most notable exit was Amylyx Pharmaceuticals, an estimated $14.8M position sold in full.

By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 38% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Tybourne Capital Management added an estimated $31.6M to NVIDIA.

  • Tybourne Capital Management added most to NVIDIA in Q3 2022, an estimated $31.6M increase.
  • Tybourne Capital Management's biggest Q3 2022 reduction was Amazon, cutting an estimated $31.8M.
  • Tybourne Capital Management fully exited Amylyx Pharmaceuticals in Q3 2022, selling an estimated $14.8M.
  • Tybourne Capital Management's ten largest holdings make up 64% of its $1.04B portfolio in Q3 2022.
  • Tybourne Capital Management opened 0 new positions and closed 1 in Q3 2022.
  • Tybourne Capital Management's portfolio value fell 25% quarter-over-quarter to $1.04B.

Based on Tybourne Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.